Genentech, Inc.
NEWS
Recently, BioSpace posted a question on its website, under the heading, “We Want to Hear from You! Top Life Sciences Trends.” Let’s take a look at the five trends survey participants mentioned.
This morning, Genentech released results of its Phase III IMpower 133 trial that showed treatment with Tecentriq plus chemotherapy helped people with extensive-stage small cell lung cancer live significantly longer than with chemotherapy alone.
Ovarian cancer is the fifth leading cause of cancer-related deaths in the United States. It is estimated that this year there will be more than 22,000 women in the U.S. diagnosed with the disease and about 14,000 disease-related deaths.
Hemophilia patients could have an easier time taking their medication if the U.S. Food and Drug Administration (FDA) gives the green light for the newest indication of Genentech’s Hemlibra for patients who do not have Factor VIII inhibitors.
Days after a report by The New York Times and ProPublica revealed José Baselga, chief medical officer at Memorial Sloan Kettering Cancer Center, failed to disclose his vast financial ties to various companies in journal articles, the noted cancer researcher has resigned from his position.
Last year’s influenza season in the U.S. had record-breaking hospitalization rates. A lot of industry observers are looking at a new flu drug, baloxavir marboxil, for which clinical trial data was just published.
It’s been a hot year for biotech initial public offerings (IPOs). Two recent announced offerings, Kodiak Sciences in Palo Alto and Guardant Health in Redwood City mark the fourteenth and fifteenth life sciences IPOs in the San Francisco Bay Area this year.
Job hunting can be a challenging time for people. Finding open positions that fit your skill set and then competing with other highly-qualified people can be bruising, especially if you’re already a bit damaged from a recent layoff.
Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let’s take a look.
JOBS
IN THE PRESS